Nasdaq IPOs

New Beginnings Acquisition, a blank check company formed by the co-founder of Crescent Heights and an executive from Alliant Insurance Services, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Miami, FL-based company plans to raise $75 m

Mallard Acquisition, a blank check company formed by Mallard Capital targeting an industrials business, filed on Monday with the SEC to raise up to $100 million in an initial public offering. The Cornelius, NC-based company plans to raise $100 million by offering 10 million units

VIA optronics, a German provider of sunlight readable, ultrathin display and touch solutions, announced terms for its IPO on Monday. The Nuremberg, Germany-based company plans to raise $100 million by offering 6.3 million ADSs at a price range of $15 to $17. The company plans to

Graybug Vision, a Phase 2 biotech developing transformative medicines for ocular diseases, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the pr

Orphazyme, a Danish late-stage biotech developing protein therapies for rare neurodegenerative diseases, announced terms for its IPO on Monday. The Copenhagen, Denmark-based company plans to raise $100 million by offering 7.6 million ADSs at $13.13, the as-converted September 17t

PMV Pharmaceuticals, an early stage biotech developing targeted therapies for cancer, announced terms for its IPO on Monday. The Cranbury, NJ-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed r

Prelude Therapeutics, a phase 1 biotech developing small molecule therapies for cancer, announced terms for its IPO on Monday. The Wilmington, DE-based company plans to raise $150 million by offering 8.3 million shares at a price range of $17 to $19. At the midpoint of the propos

ArcLight Clean Transition Corp., a blank check company formed by ArcLight Capital Partners targeting a renewable energy business, lowered the proposed deal size for its upcoming IPO on Monday. The Boston, MA-based company now plans to raise $250 million by offering 25 million uni

In another busy week for the September IPO market, eight IPOs are scheduled to raise $2.0 billion, led by prescription drug marketplace GoodRx Holdings (GDRX).  The largest deal of the week, GoodRx (GDRX) plans to raise $900 million at an $11.2 billion market

In another busy week for the September IPO market, eight IPOs are scheduled to raise $2.0 billion, led by prescription drug marketplace GoodRx Holdings (GDRX).  The largest deal of the week, GoodRx (GDRX) plans to raise $900 million at an $11.2 billion market

In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the week’s diverse group of IPOs. The ye

In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the week’s diverse group of IPOs. The ye

Huadi International Group, which manufactures steel pipe and tube products in China, filed on Friday with the SEC to raise up to $25 million in an initial public offering. The Wenzhou, China-based company was founded in 2018 and booked $59 million in sales for the 12 months ended

Spruce Biosciences, a Phase 2 biotech developing novel therapies for rare endocrine disorders, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The company's lead candidate, tildacerfont, is being developed for classic congenital adrenal hype

FirstMark Horizon Acquisition, a blank check company formed by FirstMark Capital targeting a US-based tech business, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company company plans to raise $300 million by

Kronos Bio, a Phase 2 biotech developing kinase inhibitor therapies for leukemia and solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company's lead candidate, entospletinib (ENTO), is an orally administered, selective sple

Shattuck Labs, a Phase 1 biotech developing dual-sided fusion protein therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company's lead candidate, SL-172154, is designed to simultaneously inhibit the CD47/SI

Social Capital Hedosophia Holdings VI, the sixth blank check company formed by Social Capital and Hedosophia targeting a tech business, filed on Friday with the SEC to raise up to $1.0 billion in an initial public offering. The Palo Alto, CA-based company plans to raise $1.0 bill

Social Capital Hedosophia Holdings V, the fifth blank check company formed by Social Capital and Hedosophia targeting a tech business, filed on Friday with the SEC to raise up to $650 million in an initial public offering. The Palo Alto, CA-based company plans to raise $650 milli

Social Capital Hedosophia Holdings IV, the fourth blank check company formed by Social Capital and Hedosophia targeting a tech business, filed on Friday with the SEC to raise up to $350 million in an initial public offering. The Palo Alto, CA-based company plans to raise $350 mil